In conclusion, a gene therapy construct has been designed that aims to provide long-term signaling via the BDNF-TrkB pathway and neuroprotection against a variety of pathophysiological insults that are encountered in neurological diseases ranging from glaucoma to Alzheimer's disease. The gene discussed is NTRK2; the disease is early-onset autosomal dominant Alzheimer disease.